肿瘤细胞治疗研究
ALL SOURCES
Empowerment of CAR-T Cells by IL-7 and IL-15 Boosts Their Efficacy Against HER2-Positive Tumors with Enhanced Expansion and Persistence.
这些发现表明，将 IL-7 和 IL-15 纳入 CAR-T 细胞生产流程可显著改善扩增、持久性和效应功能，支持将其作为一种策略来增强 CAR-T 细胞对抗实体瘤的性能。
A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cel
抗 CD19 嵌合抗原受体（CAR）T 细胞疗法治疗难治性 B 细胞恶性肿瘤显示出优异的治疗效果。
Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.
嵌合抗原受体（CAR）T 细胞过继细胞治疗彻底改变了某些 B 细胞恶性肿瘤的治疗，但对实体瘤一直无效。
IDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers.
基于嵌合抗原受体（CAR）T 细胞的疗法在治疗其他方法难以治愈的癌症、尤其是 B 细胞恶性肿瘤方面显示出显著疗效。
共 4 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
